Fig. 7

An in vivo validation for the activation of the JAK/STAT3 pathways by CM from M1-like TAMs. A. An increased expression of p-Stat3 in the OSCC xenografts treated by CM from M1-like TAMs (200x); B. Ruxolitinib (50 mg/kg, i.p. every other day) significant reduced the tumor forming of OSCC cells treated with CM from M1-like TAMs; C-E. Ruxolitinib significant reduced the expression of Ki67 (C), N-cadherin (D), and Vimentin (E) in the OSCC xenografts treated by CM from M1-like TAMs (200x); **p< 0.01